THERAPY DOSSIER · th-46c4c5cb4832

Nicotinamide adenine dinucleotide (NAD+)

Drug · No ChEMBL mechanism record; coenzyme / redox cofactor

Evidence & regulatory context

Mechanism: No ChEMBL mechanism record; coenzyme / redox cofactor
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL1234613 ↗
ChEMBL max phase: 2 / 4 (development scale, not regulatory approval)
Synonyms: NAD+; Nadide; Coenzyme I; beta-NAD; DPN
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT06505967 ↗NAunknown

Effectiveness of Qualia NAD+ supplementation on intracellular NAD levels

NAD+ Levels in the Blood

Enrolment: 200 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 22352983 ↗2012Mixed findings

Prevention of traumatic brain injury-induced neuron death by intranasal delivery of nicotinamide adenine dinucleotide.

RatTBIWeight-drop / impact-accelerationSprague-DawleyMaleIntranasal20 mg/kgImmediately after traumatic brain injury

Model: Weight-drop traumatic brain injury causing cortical and hippocampal neuronal death

Intranasal NAD+ protected neurons in hippocampal CA1, CA3 and dentate gyrus but not in the cortex, and reduced delayed microglial activation at 7 days; superoxide production and PARP-1 accumulation were unaffected.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…